Skip to main content
. 2020 Oct 29;35(2):312–332. doi: 10.1038/s41375-020-01072-6

Fig. 4. Frequency of adverse events with ibrutinib, acalabrutinib, and zanubrutinib.

Fig. 4

A The comparison of any grade adverse events in ibrutinib, acalabrutinib, and zanubrutinib. B The comparison of grade 3-5 adverse events in ibrutinib, acalabrutinib, and zanubrutinib.